{"classes":[{"categories":[{"measurements":[{"comment":"Median and upper limit of 95% CI could not be estimated due to insufficient number of participants with events.","groupId":"OG000","lowerLimit":"23.7","upperLimit":"NA","value":"NA"},{"comment":"Upper limit of 95% CI could not be estimated due to insufficient number of participants with events.","groupId":"OG001","lowerLimit":"9.1","upperLimit":"NA","value":"17.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"19"}],"units":"Participants"}],"title":"First Line Treatment"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13.9","upperLimit":"25.1","value":"19.7"},{"groupId":"OG001","lowerLimit":"10.4","upperLimit":"18.7","value":"16.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"title":"Second Line Treatment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"27"}],"units":"Participants"}],"description":"OS was defined as the time from the date of first dose to death due to any cause. If a participant was not known to have died at the time of the cutoff for analysis, then OS was censored at the date of last contact. In this outcome measure, OS for first line (no prior treatment) and second line (participant received a prior treatment defined as advanced/metastatic or locoregional disease or maintenance or if neoadjuvant/adjuvant with a disease recurrence occurred during or within 6 months of the last dose of therapy) was presented. Analysis was performed using Kaplan Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received encorafenib 300 milligrams (mg) once daily (QD) orally (received after Cycle 1 Day 3) and cetuximab 500 mg per square meters (mg/m\\^2) intravenous (IV) infusion for 120 minutes once every 2 weeks (Q2W) along with fluorouracil 400 mg/m\\^2 IV bolus then 2400 mg/m\\^2 continuous IV infusion over 46-48 hours Q2W; leucovorin 400 mg/m\\^2 IV infusion for 120 minutes Q2W and irinotecan 180 mg/m\\^2 as IV infusion for 90 minutes Q2W. Participants received treatment in 28-day cycles.","id":"OG000","title":"SLI: Cohort 1 [EC + FOLFIRI]"},{"description":"Participants received encorafenib 300 mg QD orally and cetuximab 500 mg/m\\^2 IV infusion for 120 minutes Q2W along with fluorouracil 400 mg/m\\^2 IV bolus then 2400 mg/m\\^2 continuous IV infusion over 46-48 hours Q2W; leucovorin 400 mg/m\\^2 IV infusion for 120 minutes Q2W and oxaliplatin 85 mg/m\\^2 IV infusion for 120 minutes Q2W. Participants received treatment in 28-day cycles.","id":"OG001","title":"SLI: Cohort 2 [EC + mFOLFOX6]"}],"paramType":"MEDIAN","populationDescription":"The FAS for SLI included all participants who were randomized in the SLI portion of the study. Here, \"Number Analyzed\" signifies participants evaluable for specified rows. All participants under \"Overall Number of Participants Analyzed\" contributed data to the table but may not have data evaluable for each row.","reportingStatus":"POSTED","timeFrame":"From date of first dose to death due to any cause or censoring date, whichever occurred first (maximum up to 33.9 months)","title":"SLI: Overall Survival (OS) According to Line of Therapy - FAS","type":"SECONDARY","unitOfMeasure":"Months"}